Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative capecitabine dose-finding within a DOC regimen for gastroesophageal adenocarcinoma
NL-OMON61395Phase 1Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capecitabine in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by Erasmus MC. Primary endpoint: Maximum tolerated dose of perioperative capecitabine within DOC. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NL-OMON61395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61395.